


Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma

Graphical abstract



Highlights

- We identified 8 MVI preoperative risk factors in HCC, including radiomic features.
- Radiomic features do not provide significant added value to radiologist scores.
- A model integrating clinic-radiologic and radiomic features demonstrates good performance for predicting MVI.

Authors

Xun Xu, Hai-Long Zhang, Qiu-Ping Liu, ..., Xu Yan, Yu-Dong Zhang, Xi-Sheng Liu

Correspondence

njmu_zyd@163.com
(Y.-D. Zhang), njmu_lxs@163.com
(X.-S. Liu)

Lay summary

The most effective treatment for hepatocellular carcinoma (HCC) is surgical removal of the tumor but often recurrence occurs, partly due to the presence of microvascular invasion (MVI). Lacking a single highly reliable factor able to preoperatively predict MVI, we developed a computational approach to predict MVI and the long-term clinical outcome of patients with HCC. In particular, the added value of radiomics, a newly emerging form of radiography, was comprehensively investigated. This computational method can enhance the communication with the patient about the likely success of the treatment and guide clinical management, with the aim of finding drugs that reduce the risk of recurrence.



Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma

Xun Xu^{1,4,5}, Hai-Long Zhang^{1,4,5}, Qiu-Ping Liu¹, Shu-Wen Sun¹, Jing Zhang², Fei-Peng Zhu¹,
Guang Yang², Xu Yan³, Yu-Dong Zhang^{1,*}, Xi-Sheng Liu^{1,*}

¹Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China; ²Shanghai Key Laboratory of Magnetic Resonance, East China Normal University, Shanghai, China; ³MR Scientific Marketing, Siemens Healthcare, Shanghai, China

Background & Aims: Microvascular invasion (MVI) impairs surgical outcomes in patients with hepatocellular carcinoma (HCC). As there is no single highly reliable factor to preoperatively predict MVI, we developed a computational approach integrating large-scale clinical and imaging modalities, especially radiomic features from contrast-enhanced CT, to predict MVI and clinical outcomes in patients with HCC.

Methods: In total, 495 surgically resected patients were retrospectively included. MVI-related radiomic scores (R-scores) were built from 7,260 radiomic features in 6 target volumes. Six R-scores, 15 clinical factors, and 12 radiographic scores were integrated into a predictive model, the radiographic-radiomic (RR) model, with multivariate logistic regression.

Results: Radiomics related to tumor size and intratumoral heterogeneity were the top-ranked MVI predicting features. The related R-scores showed significant differences according to MVI status ($p < 0.001$). Regression analysis identified 8 MVI risk factors, including 5 radiographic features and an R-score. The R-score (odds ratio [OR] 2.34) was less important than tumor capsule (OR 5.12), tumor margin (OR 4.20), and peritumoral enhancement (OR 3.03). The RR model using these predictors achieved an area under the curve (AUC) of 0.909 in training/validation and 0.889 in the test set. Progression-free survival (PFS) and overall survival (OS) were significantly different between the RR-predicted MVI-absent and MVI-present groups (median PFS: 49.5 vs. 12.9 months; median OS: 76.3 vs. 47.3 months). RR-computed MVI probability, histologic MVI, tumor size, and Edmondson-Steiner grade were independently associated with disease-specific recurrence and mortality.

Conclusions: The computational approach, integrating large-scale clinico-radiologic and radiomic features, demonstrates good performance for predicting MVI and clinical outcomes.

However, radiomics with current CT imaging analysis protocols do not provide statistically significant added value to radiographic scores.

Lay summary: The most effective treatment for hepatocellular carcinoma (HCC) is surgical removal of the tumor but often recurrence occurs, partly due to the presence of microvascular invasion (MVI). Lacking a single highly reliable factor able to preoperatively predict MVI, we developed a computational approach to predict MVI and the long-term clinical outcome of patients with HCC. In particular, the added value of radiomics, a newly emerging form of radiography, was comprehensively investigated. This computational method can enhance the communication with the patient about the likely success of the treatment and guide clinical management, with the aim of finding drugs that reduce the risk of recurrence.

© 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common primary hepatic malignant tumors and its incidence is increasing worldwide.¹ It is the second leading cause of cancer-specific mortality in the Asia-Pacific regions, and especially in China.² Surgical resection and liver transplantation (LT) are potentially curative for patients with HCC,³ but recurrence after surgical treatment is common. Some studies maintained that approximately 70% of patients would suffer from recurrence within 5 years after surgical resection, and 35% after LT.⁴⁻⁸

Microvascular invasion (MVI) is one of the most important prognostic factors for HCC after surgical treatment.⁹⁻¹¹ Contrary to macrovascular invasion, which can be detected with diagnostic imaging, MVI is a histologic finding that can only be postoperatively diagnosed with a surgical specimen.¹² Preoperative prediction of MVI is still challenging. A variety of imaging findings have been described, with variable diagnostic utility. Previous studies found that imaging features such as tumor size, multinodular tumor morphology, tumor margins, and peritumoral enhancement were associated with MVI.¹³⁻¹⁵ In addition, Renzulli *et al.* showed that a 2-trait predictor of venous invasion can be a useful preoperative predictor of MVI.¹⁴ Banerjee *et al.* showed that a radio-genomic venous invasion (RVI) predictor, based on the association between imaging features and gene expression, achieves high accuracy in predicting MVI in HCC.⁸

Keywords: Microvascular invasion; Clinical outcome; HCC; Radiomics; Liver imaging score.

Received 12 October 2018; received in revised form 30 January 2019; accepted 16 February 2019; available online 13 March 2019

* Corresponding authors. Addresses: Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, Jiangsu Province 210029, China. Tel.: +86 158 0515 1704 (Y.-D. Zhang), or Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, Jiangsu Province 210009, China. Tel.: +86 138 1408 6580 (X.-S. Liu).

E-mail addresses: njmu_zyd@163.com (Y.-D. Zhang), njmu_lxs@163.com (X.-S. Liu).

⁴ Xun Xu and Hai-Long Zhang are co-first authors.

⁵ Equally contributed to the study.



However, these criteria for a preoperative imaging diagnosis of MVI in HCC have not yet been widely recognized.

Radiomics is a newly emerging form of imaging analysis using a series of data-mining algorithms or statistical analysis tools on high-throughput imaging features to obtain predictive or prognostic information. By building appropriate models with refined features, it achieved successful assessment and prediction abilities in various challenging clinical tasks.^{16–19} A landmark study in colorectal cancer revealed clear associations between CT radiomics and lymph node metastases, and a combination of radiomic and clinico-radiologic factors could achieve significant clinical benefits.²⁰ However, despite its potential, the use of radiomics as a clinical biomarker still necessitates amelioration and standardization.²¹ Greater integration between radiomics and other sources of data is required for clinicians to fully and confidently accept its role in patient management. To the best of our knowledge, only one study to date has assessed the prognostic aspect of radiomics for MVI in a group of 304 patients with HCC.²² However, stronger evidence is needed in support of the implications for tumor progression and the reliability of the methodology. Additionally, MVI concerns tumor edges, while in previous studies radiomic features were only extracted inside the tumor, where by definition there is no microvascular involvement. A more effective evaluation should focus on the radiomic features at the tumor periphery.

The purpose of this study was to investigate whether a computational approach integrating large-scale clinical and imaging modalities, especially radiomic features extracted from contrast-enhanced CT (CECT), could be useful to predict MVI and the long-term clinical outcomes in patients with HCC. Additionally, the added value provided by radiomics to evidence-based clinico-radiologic factors was investigated.

Material and methods

Patients

This retrospective study involved standard care performed at a single medical institution. Ethics committee approval was granted by the local institutional ethics review board, and the requirement for written informed consent was waived. All procedures involving human participants were performed in accordance with the 1975 Helsinki declaration and its later amendments.

We queried our institution's medical records to derive all surgically confirmed cases of HCC between January 2009 and August 2017. A total of 619 confirmed cases of HCC were screened in this query. Among these, 495 consecutive patients (417 males and 78 females; mean age, 56.6 ± 11.4 years; range, 25–86 years) were identified who underwent surgical resection ($n = 479$) or LT ($n = 16$) and formed the primary cohort, according to the patient recruitment pathway and the inclusion and exclusion criteria listed in the [supplementary information \(Fig. S1\)](#).

Routine preoperative laboratory examinations included liver and renal function tests, hepatitis B and C immunology, serum α -fetoprotein (AFP) level, Child-Pugh class, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TB), conjugated bilirubin (CB), serum albumin (ALB), platelet count (PLT), prothrombin time (PT), international normalized ratio (INR), and serum creatinine (Scr). The preoperative diagnosis of HCC was based on the crite-

ria of the American Association for the Study of Liver Diseases (AASLD).²³

Histopathology

All patients underwent surgical treatment within 2 weeks of CECT examination. All surgical specimens were examined by 2 pathologists, in particular to detect the presence of MVI. The histologic parameters ordinarily included Edmondson-Steiner grade, size, number, surgical margin and MVI status of the resected tumor. MVI was defined as the presence of tumor in a portal vein, hepatic vein, or a large capsular vessel of the surrounding hepatic tissue lined by endothelium that was visible only on microscopy. Additionally, the histologic grade of liver fibrosis at the tumor periphery was reported on the basis of the Scheuer scoring system, where grades $\geq G2$, $\geq G3$, and $=G4$ indicated significant fibrosis, advanced fibrosis, and cirrhosis, respectively.

Follow-up

Patients were consistently followed-up after liver resection at intervals of 3 to 6 months, based on AFP and imaging examinations, and the time of disease-specific progression (local recurrence or distant organ metastasis) or death was recorded. Patients were censored in case of emigration, or on 31 Dec 2018, whichever came first.

Radiographic evaluation

Our protocol requirements for CECT imaging met the criteria recommended by the AASLD guideline.²³ The technical specifications of CT imaging are described in the [supplementary information \(S-text-1\)](#).

All CECT images were retrospectively interpreted by 2 radiologists (Z.H., 3 years of liver imaging experience, and Z.Y., 10 years of liver imaging experience) who were blinded to the clinical and pathological data. Both readers were members of the institution's liver disease management team and had read >2,000 liver CT studies. Before the study, they followed a whole day lecture-based and hands-on instruction session that explained in detail a structural liver imaging score (LI-score) system. During the session 100 cases randomly selected from the institutional PACS database (not included in this study cohort) were reviewed individually, scored, and then reviewed as a group.

The LI-score method, partly referring to Renzulli *et al.*¹⁴ and Banerjee *et al.*,⁸ consisted of 12 primary imaging features: i) lobes with tumor involvement (0, 1 lobe involved; 1, more than 1 lobe involved); ii) number of lesions detected (0, 1 lesion; 1, more than 1 lesion); iii) maximum tumor length (0, L-max: ≤ 5 cm; 1, L-max >5 cm); iv) tumor margin (0, smooth margin; 1, non-smooth margin); v) tumor growth pattern (0, intrahepatic growth; 1, extrahepatic growth); vi) intratumor necrosis (0, absent; 1, present); vii) intratumor hemorrhage (0, absent; 1, present); viii) pseudo-capsules (0, well-defined pseudo-capsules; 1, ill-defined pseudo-capsules); ix) peritumoral arterial enhancement (0, absent; 1, present); x) peritumoral star lesion (0, absent; 1, present); xi) intratumoral vascularity (0, hypo-/mild arterial enhancement; 1, hyper-arterial enhancement); and lastly, xii) a 2-point RVI (0, RVI-absent; 1, RVI-present) recorded on the basis of independent estimations from internal arteries (0, absent; 1, present) and hypodense halos (0, absent; 1, present).

All cases were scored individually first and then reviewed together by the 2 readers 2 weeks after the individual evaluation. Any disagreement between the readers was discussed until a final consensus was generated. Individual scores were used for the calculation of inter-observer agreement, and consensus scores were used for classifying performance. When patients had multiple liver lesions, LI-score evaluation was assessed on the largest lesion.

Radiomics analysis

In the next step, 3 radiologists (L.Q., reader #3, radiology resident; X.X., reader #4, 5 years of liver imaging experience; and Z.F., reader #5, 10 years of liver imaging experience) who were not involved in the LI-score assignment were involved in radiomics analysis.

Tumor segmentation was performed with a dedicated in-house software written in Python 3.6.1 (<https://www.python.org>) on 1.5 mm arterial-phase and 1.5 mm portal-venous-phase CT images. The software allows the semi-automatic identification of the entire-volumetric interest (VOI^{entire}) of the tumor with a combination of automatic segmentation algorithm and a manual approach (Fig. 1). Then, 50% of the entire tumor volume (VOI^{50%}) and a region at a 5 mm distance from the tumor surface was automatically reconstructed on the basis of the VOI^{entire} contours with an erosion and dilation algorithm. The VOI^{50%} and VOI^{entire} were assigned to core areas of the tumor, to reflect intratumoral heterogeneity. The VOI at 5 mm distance from the tumor surface was assigned to the penumbra zone of the tumor (VOI^{penumbra}), where there is potential for microvascular involvement.

Radiomic features were extracted from each VOI using the pyradiomics package (<http://www.radiomics.io/pyradiomics.html>). The whole radiomic analysis process was integrated into an open-source software package for feature analysis and exploration deposited on the Github website (<https://github.com/salan668/FAE>). Image normalization was performed by remapping the histogram to fit within $\mu \pm 3\sigma$ (μ : mean gray-level within the VOI; σ : gray-level standard deviation). A total of 1,210 radiomic features (<https://pyradiomics.readthedocs.io/en/latest/features.html#>) for each CT imaging modality were computed for each VOI (supplementary information, S-text-2). The extracted radiomic features were normalized to a standard unit and zero-centered using the following equation:

$$\vec{x}_n \text{ normalized} = \frac{\vec{x}_n - \bar{x}_n}{\sqrt{x_{1n}^2 + x_{2n}^2 + \dots + x_{mn}^2}} \quad \text{E1, where } \vec{x}_n \text{ is the value of}$$

feature N, and \bar{x}_n is the average value of all features. To evaluate intra-observer reliability, reader #3 and reader #4 repeated feature extraction twice in a 1-week period. Reader #5 completed the remaining image segmentations, and the readout sessions were conducted over a period of 2 months. The reliability was calculated by using intra-class correlation coefficient (ICC). Radiomic features with both intra-observer and inter-observer ICC values greater than 0.9 (indicating excellent stability) were selected for subsequent investigation.

MVI-related radiomic signatures

The samples were randomly grouped into 3 sets for training (n = 300), validation (n = 50), and testing (n = 145). We used a recursive feature selection support vector machine (Ref-SVM) to develop the MVI-related radiomic signatures.^{24,25} By allowing feature interactions, Ref-SVM returns a ranking of all features by




Fig. 1. Lesion segmentation for radiomics analysis. First, (A) radiologists manually draw a seed region (yellow line) that encloses the contour of lesion and prerenal tissues, (B) then the computer automatically segmented the lesion contour with a dichotomic classification algorithm slice-by-slice, and a semi-automatic VOI^{entire} of the tumor was identified. (C) On the bases of VOI^{entire} of the tumor, a VOI^{50%} of the tumor and a region with 5 mm distance to tumor surface (VOI^{penumbra}) were automatically reconstructed. (D-F) 3-dimensional view of the VOI^{entire}, VOI^{50%} and VOI^{penumbra}, respectively. VOI, volume of interest. (This figure appears in colour on the web.)

recursively training an SVM classifier and removing the feature with the smallest ranking score: At each iteration, the feature whose removal least affects the objective function was removed. The iterations continued until the desired number of features was reached. The desired number of MVI-related features and classifier parameters were selected as those that resulted in the best overall accuracy and smallest estimate error over the training/validation data. At the end of iterations, the output of Ref-SVM model was converted into a probability score, namely the radiomic score (R-score), indicating the individual relative risk for MVI.

Development, performance, and validation of the predictive model

Uni- and multivariate analyses with an adjusted odds ratio (OR) regression model were performed to determine MVI risk factors and construct the MVI risk model, namely the radiologic-radiomic (RR) model, from multi-scale clinico-radiologic and radiomic signatures. The candidate clinical variables were age, sex, history of hepatic virus infection (0, negative; 1, history of HBV, HCV or HBV + HCV), history of cirrhosis (0, absent; 1, present), Child-Pugh class (0, class A; 1, class B or C), ALT (0, ≤ 50 U/L; 1, > 50 U/L), AST (0, ≤ 40 U/L; 1, > 40 U/L), TB (0, ≤ 19 $\mu\text{mol/L}$; 1, > 19 $\mu\text{mol/L}$), CB (0, ≤ 6.8 $\mu\text{mol/L}$; 1, > 6.8 $\mu\text{mol/L}$), ALB (0, ≤ 40 g/L; 1, > 40 g/L), PLT (0, $\leq 100 \times 10^9/\text{L}$; 1, $> 100 \times 10^9/\text{L}$), INR (0, ≤ 1.0 ; 1, > 1.0), PT (0, ≤ 13 s; 1, > 13 s), AFP (0, ≤ 400 ng/ml; 1, > 400 ng/ml), and Scr (0, ≤ 133 $\mu\text{mol/L}$; 1, > 133 $\mu\text{mol/L}$). Radiologic features included the 12 LI-scores assigned by radiologists, as well as 6 two-point R-scores measured from arterial and portal-venous phase in $\text{VOI}^{50\%}$, $\text{VOI}^{\text{entire}}$, and $\text{VOI}^{\text{penumbra}}$. The threshold of R-scores was determined using receiver operating characteristic (ROC) analysis by maximizing the Youden index.

Variables significantly associated with MVI by univariate analyses were selected as candidates for step-wise multivariate analysis. The RR model was formulated based on the results of multivariate regression. The model is based on proportionally converting each regression coefficient in multivariate logistic regression to a 0- to 100-point scale. The effect of the variable with the highest β coefficient (absolute value) is assigned 100 points. The points are added across independent variables to derive total points, which are converted to predicted probabilities (Pi).

Statistical analysis

The discrimination performance of the RR model was quantified by the area under the ROC curve (AUC) value in the primary training/validation set and internally validated in the independent test set. Additionally, a decision curve analysis was performed to evaluate the clinical usefulness and net benefits of the developed radiomic signatures. The decision curve estimates the net benefit of a model as the difference between the true-positive and false-positive rates, weighted by the odds of the selected threshold probability of risk.²⁶

Disease-specific survival was computed from the date of surgery to date of death or censored at the date of last follow-up. Progression-free survival (PFS) and overall survival (OS) were defined as the interval between surgery and radiographic detection of recurrence, last follow-up, or death. Survival curves were generated with the Kaplan-Meier method and compared by a 2-sided log-rank test. Univariate and multivariate analyses with Cox proportional hazards regression determined the predictors of disease-specific recurrence and mortality. Variables that

reached statistical significance in the univariate analysis were considered for the multivariate model. Statistical analysis was performed using the R software (version 3.4.4, R Project for Statistical Computing, <http://www.r-project.org>). Two-sided *p* values less than 0.05 were considered statistically significant.

Results

Basic clinico-radiologic characteristics

Out of 495 patients included, histologic MVI was diagnosed in explanted tissue of 149 patients (30.1%). Patients with MVI were younger, and had higher ALT, AST, PLT, INR and AFP levels than those without MVI. The 2 groups were similar in their distribution of sex, hepatic virus infection, cirrhosis, Child-Pugh stage, TB, CB, ALB, PT and Scr test. Risk coefficient estimated by univariate analysis is summarized in Table 1. HCCs with and without MVI demonstrated significantly different imaging features when assessed with the structural LI-scoring method (Table 2).

Radiomic analysis

Radiomic features were selected and quantitatively integrated into 6 R-scores on the basis of $\text{VOI}^{50\%}$, $\text{VOI}^{\text{entire}}$, and $\text{VOI}^{\text{penumbra}}$ from the arterial and portal-venous phase CECT images of the primary training/validation cohort (Fig. S2). The AUCs of the R-scores in the test set were very close to those of the training/validation set, suggesting a good reproducibility of the newly developed radiomic signatures in internal validation (Table 3).

The R-scores showed a significant difference ($p < 0.001$) between the MVI-absent and MVI-present groups (Fig. S3). The 6 R-scores had similar diagnostic performance for histologic MVI status, with pairwise comparison of ROC curves showing no significant differences (AUC, 0.798–0.823; $p > 0.05$; Fig. S4).

Predictive RR model

Among all clinico-radiologic and radiomic factors, 19 significant predictors including 6 clinical variables (age, ALT, AST, PLT, INR, and AFP), 11 LI-scores (all except intratumoral hemorrhage) and 6 R-scores were identified by univariate analysis. In the multivariate regression model, 8 predictors were independent prognostic factors of histologic MVI: higher AST (> 40 U/L), higher AFP (> 400 ng/ml), non-smooth tumor margin, extrahepatic growth pattern, ill-defined pseudo-capsule, peritumoral arterial enhancement, presence of RVI, and higher R-score ($\text{VOI}^{\text{entire}}$) (Fig. 2A). These independently associated risk factors were used to form the RR model, described by the formula: $Y = -5.58 + 0.69 \times \text{AST} + 0.70 \times \text{AFP} + 1.43 \times \text{tumor margin} + 0.74 \times \text{growth pattern} + 1.63 \times \text{capsule} + 1.11 \times \text{peritumoral enhance} + 0.80 \times \text{RVI} + 0.85 \times \text{R-score} (\text{VOI}^{\text{entire}})$ (Fig. 2B).

The resulting RR model demonstrated good accuracy in estimating the risk of MVI, with an AUC of 0.909 (95% CI 0.869–0.928) in the training/validation set and 0.889 (95% CI 0.851–0.919) in the test set (Fig. 3A). The calibration curve of the model demonstrated good agreement between predicted and observed MVI in both the training/validation and the test set (Fig. 3B); The Hosmer-Lemeshow test gave a chi-square of 5.44 ($p = 0.71$) for the training/validation set and 6.55 ($p = 0.59$) for the test set, indicating that the RR model was appropriate in both data sets. Using an optimal threshold chosen to maximize the Youden index of the ROC analysis from the training/validation data, the diagnostic performance of the RR model is summarized in Table 4.

Table 1. The clinical and histologic characteristics of primary cohort.

Variable	MVI- (n = 346)	MVI+ (n = 149)	Estimate risk [†]	p value [*]
Clinical stage				
I stage	266 (76.9)	11 (7.4)	1	
II stage	31 (8.9)	66 (44.3)	1.613 (0.981–3.032)	0.031
≥III stage	49 (14.2)	72 (48.3)	5.786 (3.715–9.010)	<0.001
Age				
0, ≤50 yr	102 (29.5)	61 (40.9)	1	
1, >50 yr	244 (70.5)	88 (59.1)	0.591 (0.396–0.883)	0.004
Sex				
0, Male	290 (83.8)	127 (85.2)	1	
1, Female	56 (16.2)	22 (14.8)	0.910 (0.532–1.557)	0.691
Hepatic virus infection				
0, absent	43 (12.4)	14 (9.4)	1	
1, present (HBV/HCV)	303 (87.6)	135 (90.6)	1.305 (0.688–2.474)	0.193
Cirrhosis				
0, absent	76 (22.0)	13 (8.1)	1	
1, present	270 (78.0)	59 (39.9)	0.980 (0.616–1.558)	0.461
Child-Pugh				
0, A	323 (93.4)	136 (91.3)	1	
1, B + C	23 (6.6)	13 (8.8)	1.334 (0.657–2.711)	0.264
ALT				
0, ≤50 U/L	269 (77.7)	95 (63.8)	1	
1, >50 U/L	77 (22.3)	54 (36.2)	2.004 (1.317–3.051)	0.001
AST				
0, ≤40 U/L	218 (63.0)	47 (31.5)	1	
1, >40 U/L	128 (37.0)	102 (68.5)	3.662 (2.433–5.512)	<0.001
TB				
0, ≤19 μmol/L	245 (70.8)	94 (63.1)	1	
1, >19 μmol/L	101 (29.2)	55 (36.9)	1.408 (0.938–2.112)	0.090
CB				
0, ≤6.8 μmol/L	251 (72.5)	96 (64.4)	1	
1, >6.8 μmol/L	95 (27.5)	53 (35.6)	1.447 (0.960–2.181)	0.070
ALB				
0, ≤40 g/L	147 (42.5)	64 (43.0)	1	
1, >40 g/L	199 (57.5)	85 (57.0)	0.979 (0.664–1.444)	0.923
PLT				
0, ≤100 × 10 ⁹ /L	102 (29.5)	29 (19.5)	1	
1, >100 × 10 ⁹ /L	244 (70.5)	120 (80.5)	1.744 (1.093–2.782)	0.020
INR				
0, ≤1.0	67 (19.4)	17 (11.4)	1	
1, >1.0	279 (80.6)	132 (88.6)	1.878 (1.061–3.325)	0.031
PT				
0, ≤13 s	249 (72.0)	98 (65.8)	1	
1, >13 s	97 (28.0)	51 (34.2)	1.328 (0.878–2.001)	0.167
Scr				
0, ≤133 μmol/L	340 (98.3)	149 (100.0)	/	
1, >133 μmol/L	6 (1.7)	0 (0.0)	/	0.106
AFP				
0, ≤ 400 ng/mL	250 (72.3)	55 (36.9)	1	
1, > 400 ng/mL	96 (27.7)	94 (63.1)	4.545 (3.021–6.840)	<0.001
Histologic no of tumors				
<3	320 (92.5)	127 (85.2)		
≥3	26 (7.5)	22 (14.8)		
Surgical size (cm), mean (SD)	4.9 (3.3)	8.7 (4.2)		<0.001
Edmondson–Steiner grade				
I	167 (48.3)	33 (22.1)		
II	154 (44.5)	91 (61.1)		
III	25 (7.2)	25 (16.8)		

Unless indicated otherwise, data are number of tumors, with percentages in parentheses. AFP, serum alpha-fetoprotein; ALB, serum albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CB, conjugated bilirubin; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; PLT, platelet count; PT, prothrombin time; Scr, serum creatinine; TB, serum total bilirubin.

[†]Odds ratio with univariate test.

^{*}Chi-square test.

Table 2. The imaging features of patients between MVI- and MVI+ group.

Variable	MVI- (n = 346)	MVI+ (n = 149)	Estimate Risk [†]	p [*]
No. of nodes				
0, 1	295 (85.3)	107 (71.8)	1	<0.001
1, ≥2	51 (14.7)	42 (18.2)	2.255 (1.417–3.588)	
No. of lobe involved				
0, 1	190 (54.9)	34 (22.8)	1	0.001
1, ≥2	156 (45.1)	115 (77.2)	4.076 (2.632–6.314)	
L-max				
0, ≤5 cm	217 (62.7)	29 (19.5)	1	<0.001
1, >5 cm	129 (37.3)	120 (80.5)	6.778 (4.294–10.698)	
Tumor margin				
0, smooth	238 (68.8)	19 (12.8)	1	<0.001
1, non-smooth	108 (31.2)	130 (87.2)	15.155 (8.896–25.819)	
Tumor growth pattern				
0, Intrahepatic growth	230 (66.5)	60 (40.3)	1	<0.001
1, extrahepatic growth	116 (33.5)	89 (59.7)	2.954 (1.987–4.392)	
Intratumor necrosis				
0, absent	150 (43.4)	16 (10.7)	1	<0.001
1, present	196 (56.6)	133 (89.3)	6.277 (3.582–10.998)	
Intratumor hemorrhage				
0, absent	319 (92.2)	129 (86.6)	1	0.050
1, present	27 (7.8)	20 (13.4)	1.820 (0.986–3.361)	
Pseudo-capsule				
0, well-defined capsule	155 (44.8)	10 (6.7)	1	<0.001
1, ill-defined capsule	191 (55.2)	139 (93.3)	11.266 (5.731–22.149)	
Peritumoral enhance				
0, absent	336 (97.1)	129 (86.6)	1	<0.001
1, present	10 (2.9)	20 (13.4)	5.178 (2.360–11.362)	
Peritumoral star node				
0, absent	315 (91.0)	107 (71.8)	1	<0.001
1, present	31 (9.0)	42 (28.2)	3.963 (2.372–6.622)	
Intratumor vascularity				
0, hypo-/mild	62 (17.9)	7 (4.7)	1	<0.001
1, hyper-	284 (82.1)	142 (95.3)	4.373 (1.950–9.806)	
RVI score				
0, absent	224 (64.7)	26 (17.4)	1	0.001
1, present	122 (35.3)	123 (82.6)	8.719 (5.409–14.054)	

Unless indicated otherwise, data are number of tumors, with percentages in parentheses.

[†]Odds ratio with univariate test.

^{*}Chi-square test. MVI, microvascular invasion; RVI, radio-genomic venous invasion.

As part of this study, we also tested the incremental value of the R-scores with respect to LI-scores for predicting MVI using a decision curve analysis, as described in Fig. S5. Decision curves were estimated using LI-scores and LI-scores added with R-scores, respectively, and showed that adding the R-scores did not result in a net benefit compared with the use of conventional LI-scores.

Predictors of survival

As of Dec. 2018, 405/495 (81.8%) patients had completed the PFS follow-up and 439/495 (88.7%) had completed the OS follow-up. The overall recurrence rate was 48.9% (198/405) and the overall death rate was 34.5% (151/438).

The median PFS of the patients was 38.3 (range, 27.1–47.8) months, and in particular 9.2 (5.8–18.6) months for those with MVI and 46.7 (38.3–66.4) months for those without MVI (log-rank test, *p* <0.001). Similar results were observed in the RR model: The median PFS was 12.9 (7.1–25.5) months for patients with RR-predicted MVI presence and 49.5 (42.3–93.7) months for those with RR-predicted MVI absence (log-rank test, *p* <0.001).

The median OS for all patients was 64.4 (60.3–68.6) months, and specifically 42.3 (33.8–50.9) months for those with MVI and 72.5 (68.0–76.9) months for those without MVI (log-rank test, *p* <0.001). The median OS was 47.3 (40.6–54.1) months for those with RR-predicted MVI presence and 76.3 (71.6–80.8) months for those with RR-predicted MVI absence (log-rank test, *p* <0.001, Fig. 4).

Clinical stage (0, stage I-II; 1, stage ≥III), histologic findings such as tumor size, number of tumors (0, No. <3; 1, No. ≥3), Edmondson-Steiner grade (0, grade I; 1, grade II; 2, grade III), and histologic MVI, as well as the RR-predicted Pi were assessed as survival predictors by means of multivariate Cox regression. The results showed that RR-predicted Pi (OR 1.57; 95% CI 0.96–2.56), histologic MVI (OR 1.49; 95% CI 1.01–2.22), and tumor size (OR 1.05; 95% CI 1.01–1.11) were independent predictors of disease-specific recurrence. Edmondson-Steiner grade (OR 3.02; 95% CI 2.06–4.42), MVI (OR 1.70; 95% CI 1.10–2.62), RR-predicted Pi (OR 1.69; 95% CI 0.97–2.96), and tumor size (OR 1.05; 95% CI 1.01–1.10) were independent predictors of disease-specific mortality. A representative case is provided to

Table 3. Results of radiomics analysis with Ref-SVM approach in primary training/validation and test cohort.

Region	Features selected	Top 3 important features	R-score		
			AUC (training/validation)	AUC (test)	Cut-off value
VOI ^{50%} ap	63	(1) Original shape surface area; (2) wavelet-HLL-gldm gray level non-uniformity; (3) wavelet-LHL-gldm dependence non-uniformity	0.817 (0.771–0.842)	0.791 (0.761–0.823)	>0.32
VOI ^{entire} ap	167	(1) Original shape surface area; (2) wavelet-HLH-glszm-size zone non-uniformity; (3) wavelet-HLL-gldm gray level non-uniformity	0.821 (0.782–0.856)	0.798 (0.760–0.827)	>0.29
VOI ^{penumbra} ap	36	(1) Original shape surface area; (2) log-sigma-3-0-mm-3D-glrml run length non-uniformity; (3) wavelet-HLL-gldm Gray Level non-uniformity	0.817 (0.772–0.847)	0.794 (0.751–0.821)	>0.32
VOI ^{50%} pp	90	(1) Original shape surface area; (2) wavelet-LHL-glrml gray level non-uniformity; (3) wavelet-LLH-glszm gray level non-uniformity	0.819 (0.774–0.855)	0.787 (0.758–0.823)	>0.29
VOI ^{entire} pp	89	(1) Wavelet-HHH-ngtdm_busyness; (2) wavelet-HLH_ngtdm_complexity; (3) log-sigma-5-0-mm-3D_glszm_zone-entropy	0.841 (0.807–0.886)	0.819 (0.781–0.858)	>0.29
VOI ^{penumbra} pp	160	(1) Wavelet-LHH-glrml run length non-uniformity; (2) wavelet-LHL-glrml-gray level non-uniformity; (3) wavelet-HLL-glrml gray level non-uniformity	0.829 (0.787–0.861)	0.806 (0.773–0.837)	>0.24

*Receiver operating characteristic analysis by maximizing the Youden index. ap, arterial-phase imaging; pp, portal-venous phase imaging; Ref-SVM, recursive feature selection support vector machine; VOI, volume of interest.




Fig. 2. Forest plot and nomogram of independent predictors of MVI. (A) Forest plot of independent predictors of MVI with a multivariate regression model. (B) The model presented with a nomogram scaled by the proportional regression coefficient of each predictor. AFP, alpha-fetoprotein; AST, aspartate aminotransferase; MVI, microvascular invasion; OR, odds ratio; RVI, radio-genomic venous invasion.




Fig. 3. Receiver operating characteristic analysis and calibration curve of RR model in training/validation and test data. FP, false positive; RR, radiographic-radiomic; TP, true positive.

Table 4. Diagnostic performance of RR model for MVI status.

Method	Training/validation (n = 350)			Test (n = 145)		
	SEN	SPE	ACC	SEN	SPE	ACC
AST	69.0 (69/100)	62.0 (155/250)	64 (224/350)	69.4 (34/49)	63.5 (61/96)	65.5 (95/145)
AFP	64.0 (64/100)	70.4 (176/250)	68.6 (240/350)	65.3 (32/49)	76.0 (73/96)	72.4 (105/145)
Tumor margin	87.0 (87/100)	64.8 (162/250)	71.1 (249/350)	89.8 (44/49)	66.7 (64/96)	74.5 (108/145)
Growth pattern	60.0 (60/100)	66.0 (165/250)	64.3 (225/350)	63.3 (31/49)	66.7 (64/96)	65.5 (95/145)
Capsule	93.0 (93/100)	41.6 (104/250)	56.3 (197/250)	93.9 (46/49)	52.1 (50/96)	66.2 (96/145)
Peritumoral enhance	18.0 (18/100)	96.8 (242/250)	74.3 (260/350)	8.1 (4/49)	96.9 (93/96)	66.9 (97/145)
RVI	81.0 (81/100)	66.8 (167/250)	70.9 (248/350)	87.8 (43/49)	59.4 (57/96)	69.0 (100/145)
R-score (VOI ^{entire} ap)	73.0 (73/100)	78.0 (195/250)	76.6 (268/350)	79.6 (39/49)	75.0 (72/96)	76.6 (111/145)
R-score (VOI ^{entire} pp)	78.0 (78/100)	78.8 (197/250)	78.6 (275/350)	75.5 (37/49)	71.9 (69/96)	73.1 (106/145)
RR model	88.0 (88/100)	76.8 (192/250)	80.0 (280/350)	89.8 (44/49)	79.2 (76/96)	82.8 (120/145)

ACC, accuracy; MVI, microvascular invasion; RR, radiographic-radiomic; SEN, sensitivity; SPE, specificity.

show the discriminative ability of a computational model for stratifying MVI and predicting OS (Fig. 5).

Discussion

The aim of this study was to investigate the prognostic aspects of computational-assisted models derived from large-scale clinical and imaging data, especially radiomic features from CECT, for preoperative prediction of histologic MVI status and clinical outcomes in a cohort of 495 patients with HCC. We concluded that CT tumor radiomic features, converted into quantitative R-scores, can be independent predictors of MVI, but less relevant than radiologist scores. A risk model integrating clinico-radiologic factors and R-scores can identify more than 88% of the MVI-positive cases with a specificity of 76.8%–79.2%. Additionally, the model predictions were independently associated with disease-specific recurrence and long-term mortality, suggesting that our findings play an important role in the clinical treatment of HCC.

Radiomics has been recognized as an important imaging technology in oncology.^{16–19} Nevertheless, its use as a clinical biomarker faces several technical and methodological challenges. An important challenge is how to precisely define the

tumor boundary for radiomics analysis. The manual method is simple and effective in delimiting regions, but is challenged by poor inter-reader reliability, and the results may not reflect the true edge features of the target tumor. Instead of the manual approach or the approach consisting of drawing the single largest imaging slice, mostly used in previous studies,^{22,27,28} we used a simple dichotomic classification algorithm to semi-automatically segment the entire volumetric tumor contours. The VOI derived from this 3D segmentation can provide the entire volumetric imaging features of the tumor and may be less influenced by hand-related artifacts. Another important factor is that radiomic features are usually extracted from the intratumor regions, reflecting the biological properties related to intratumor heterogeneities. However, MVI generally occurs on the tumor edges: For this reason, we proposed a novel approach to determine multi-scale radiomic features, from the center (VOI^{50%}), the entire volume (VOI^{entire}), and the edge zone (VOI^{penumbra}) of the tumor. Interestingly, we found that the R-scores at the VOI^{penumbra} can differ according to the presence of MVI, but are not superior to features obtained from the VOI^{entire} in predicting MVI. This may imply that, in current CT imaging, we cannot observe MVI status directly from the peritumoral regions potentially associated to it. Instead, MVI status




Fig. 4. Survival curves according to histological and RR-predicted MVI status. (A,B) PFS and (C,D) OS curves scaled by histologic MVI status and RR model-predicted MVI status with Kaplan-Meier analysis. The classification of RR model-predicted MVI status was derived using the optimal threshold that maximizes the Youden index of receiver-operating characteristic analysis. MVI, microvascular invasion; RR, radiographic-radiomic; OS, overall survival; PFS, progression-free survival.

could be predicted by analyzing substantial radiomic features from both intratumoral and peritumoral regions. Among those 7,000+ radiomic features, factors related to tumor size (e.g., shape surface area) and heterogeneities (e.g., gray-level non-uniformity, wavelet busyness, complexity, and entropy) were the most important components for predicting histologic MVI. Shape surface area is a measure of the relative size of the image array, where a greater surface area implies a greater tumor size. This finding was in agreement with those of previous studies reporting tumors larger in size having higher MVI risk.¹³ Uniformity, busyness, complexity, and entropy measure the image array heterogeneity, with greater values of these factors implying greater heterogeneity or a larger range of discrete intensity values: This is partly in agreement with the findings of Akai *et al.*²⁸

However, the radiomic signatures developed in our study were less important, in the regression model, than radiologist scores such as capsule, tumor margin, and peritumoral enhancement, and the AUCs (0.787–0.841) measured from radiomics were relatively low compared to evidence-based clinico-radiologic factors reported by Renzulli *et al.*¹⁴ and Banerjee *et al.*⁸

Given the lack of a single highly reliable factor to predict MVI, computational-assisted models combining different factors associated with MVI status become a viable alternative.²⁹ Zhao *et al.*³⁰ developed a scoring model including intratumoral arteries, non-nodular HCC type, and absence of tumor capsule on preoperative contrast-enhanced CT for predicting MVI, regardless of tumor size. The AUCs of this model were 0.872 and 0.856 in the training and validation group, respectively.




Fig. 5. A representative case to show discriminative ability of computational model for classification of MVI and prediction of OS. A 68-year-old man with history of HBV infection presented with an increased AFP level ($>1,200$ ng/ml), CT showed a 4.3 cm solid mass in right lobe of liver, featured with internal arteries (A, arrow), ill-defined margin, loss of capsule and extrahepatic extension (B, C, arrow). Even the tumor size was less than 5 cm, its MVI risk calculated by RR model was 78.2%. He was confirmed MVI+ at histopathology (yellow line, D) and had a local recurrence in left liver lobe 21 months after surgery (arrow, E). AFP, alpha-fetoprotein; MVI, microvascular invasion; RR, radiographic-radiomic; OS, overall survival. (This figure appears in colour on the web.)

Lei *et al.*¹³ developed a nomogram by incorporating tumor diameter, number, capsule, AFP, platelet level, HBV-DNA load and typical MRI dynamic features to predict MVI of HBV-related HCC within the Milan criteria, resulting in an accuracy of 0.81 and 0.80 in the training and validation group, respectively. Our risk model, comprising 8 clinico-radiologic and radiomic predictors, achieved an AUC of 0.909 in the training/validation set and 0.889 in the test set. This finding was in excellent agreement with Renzulli *et al.*,¹⁴ who similarly used a combination of 3 significant imaging features, obtaining an AUC of 0.90. Among our risk factors, tumor capsule, margin and peritumoral enhancement were more important, in the regression model, than the R-score. This finding differs from the results of Peng *et al.*,²² in which the radiomic signature was the top predictor, followed by clinico-radiologic factors. Such inconsistencies among established studies might be associated with differences in population characteristics or imaging and measurement methodologies, but nevertheless question the role of radiomics in routine clinical practice.

Both R-scores and LI-scores originate from primary CT images, but analysis methods and biological implications are different. The R-scores originate in microscopic features related to tumor heterogeneities, while LI-scores are macroscopic observations of imaging features of the original lesions and surrounding areas by human experts. The R-score is limited by its complexity and the lack of algorithmic standardization, but strengthened by its high level of automaticity and lower inter-reader variability. Meanwhile, the LI-score, an expert-based evaluation, notwithstanding its reproducibility and comparabil-

ity problems, is still a basic tool to interpret the primary imaging features of HCC and predict its biological properties. Thus, combining the 2 approaches within a computational framework could be a viable alternative in clinical practice, allowing for better patient management.

Histologic MVI has been reported to be associated with poorer HCC prognosis in many studies,^{13,29,31} and we obtained similar results. In our primary cohort, patients with different RR-computed probability, histologic MVI, tumor size, and Edmondson-Steiner grade had different clinical outcomes, and those risk factors were independently associated with disease-specific recurrence and mortality, implying their prognostic relevance for the long-term management of patients.

Some limitations of this study should be noted. First, because of its retrospective character, a large number of patients who are clinically deemed “high-risk” for MVI but who did not undergo surgical management were excluded. Potential selection bias may hamper the reproducibility and comparability of the results, and the clinical usefulness of this computational approach still needs improvement and independent validation in further studies. Moreover, multi-parametric MRI has recently become an essential part of the assessment of liver neoplasia, but there is no clear consensus on whether CT or MRI are more useful for predicting histologic status in HCC, so that further studies are needed about this aspect as well. Third, in contrast to previous reports, L-max was not selected in our step-wise regression model. This can be explained by the high level of collinearity between imaging size and the R-score: The R-score retained in the model did contain size factors (*e.g.*, shape

surface area). Finally, this study was a single-center experience limited to our medical center, and expanding the study results to other medical centers will be required to validate its reproducibility.

In conclusion, we systematically investigated the outcomes of patients with HCC undergoing surgical resection with curative intent by analyzing large-scale clinical and imaging data, and especially radiomic features from CECT. We thus answered 2 important questions posed at the beginning of the study: i) The R-score, together with 7 clinico-radiologic biomarkers, forms a set of independent predictors of histologic MVI of HCC; and ii) the R-score does not provide statistically significant added value to radiologist scores in predicting MVI. Considering its automaticity and objectivity, radiomics integrated with other data sources consistently achieved positive results in our primary cohort. Therefore, this model-dependent integration will be required in future studies for clinicians to fully accept and be confident in its role in patient management.

Financial support

This work was supported by China Postdoctoral Fund (grant number 2015M580453, Z.Y.) and a Key Social Development Program for the Ministry of Science and Technology of Jiangsu Province (grant number BE2017756, Z.Y.).

Conflict of interest

The authors declare no conflicts of interest that pertain to this work.

Authors' contributions

Conception and design: Yu-Dong Zhang, Xi-Sheng Liu. Development of methodology: Xun Xu, Hai-Long Zhang, Qiu-Ping Liu, Shu-Wen Sun, Fei-Peng Zhu, Jing Zhang, Xu Yan, Guang Yang, Yu-Dong Zhang, Xi-Sheng Liu. Acquisition of data (acquired and managed patients, provided facilities, etc.): Xun Xu, Hai-Long Zhang, Qiu-Ping Liu, Shu-Wen Sun, Fei-Peng Zhu, Jing Zhang, Xu Yan, Guang Yang, Yu-Dong Zhang, Xi-Sheng Liu. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Xun Xu, Hai-Long Zhang, Qiu-Ping Liu, Shu-Wen Sun, Fei-Peng Zhu, Jing Zhang, Xu Yan, Guang Yang, Yu-Dong Zhang, Xi-Sheng Liu. Writing, review, and/or revision of the manuscript: Xun Xu, Yu-Dong Zhang, Xi-Sheng Liu. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Xun Xu, Hai-Long Zhang, Qiu-Ping Liu, Shu-Wen Sun, Fei-Peng Zhu, Jing Zhang, Xu Yan, Guang Yang, Yu-Dong Zhang, Xi-Sheng Liu. Study supervision and guarantors: Yu-Dong Zhang, Xi-Sheng Liu.

Acknowledgement

We thank the Department of Pathology of the First Affiliated Hospital of Nanjing Medical University for assistance with histopathology.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2019.02.023>.

References

- [1] Marrero JA, Welling T. Modern diagnosis and management of hepatocellular carcinoma. *Clin Liver Dis* 2009;13:233–247.
- [2] Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hep Intl* 2017;11:317–370.
- [3] Kanwal F, Befeler A, Chari RS, Marrero J, Kahn J, Afdhal N, et al. Potentially curative treatment in patients with hepatocellular cancer—results from the liver cancer research network. *Aliment Pharmacol Ther* 2012;36:257–265.
- [4] Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown Jr RS, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. *Am J Transplant* 2007;7:1601–1608.
- [5] Marshall AE, Rushbrook SM, Vowler SL, Palmer CR, Davies RJ, Gibbs P, et al. Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. *Liver Transplant* 2010;16:279–288.
- [6] Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. *J Hepatol* 2006;45:246–253.
- [7] Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. *Arch Surg* 2008;143:182–188, discussion 188.
- [8] Banerjee S, Wang DS, Kim HJ, Sirlin CB, Chan MG, Korn RL, et al. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. *Hepatology* 2015;62:792–800.
- [9] Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. *Hepatol Res* 2003;26:142–147.
- [10] D'Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. *Liver Transplant* 2009;15:1278–1287.
- [11] Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. *Surgery* 2007;141:330–339.
- [12] Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. *Ann Surg Oncol* 2013;20:325–339.
- [13] Lei Z, Li J, Wu D, Xia Y, Wang Q, Si A, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the milan criteria. *JAMA surgery* 2016;151:356–363.
- [14] Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, et al. Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? *Radiology* 2016;279:432–442.
- [15] Chandarana H, Robinson E, Hajdu CH, Drozhinin L, Babb JS, Taouli B. Microvascular invasion in hepatocellular carcinoma: is it predictable with pretransplant MRI? *AJR Am J Roentgenol* 2011;196:1083–1089.
- [16] Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. *Nat Commun* 2014;5:4006.
- [17] Kickingereder P, Gotz M, Muschelli J, Wick A, Neuberger U, Shinohara RT, et al. Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. *Clin Cancer Res* 2016;22:5765–5771.
- [18] Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. *Radiology* 2016;278:563–577.
- [19] Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z, et al. Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer. *Radiology* 2016;281:947–957.
- [20] Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. *J Clin Oncol* 2016;34:2157–2164.
- [21] Limkin EJ, Sun R, Derclé L, Zacharaki EI, Robert C, Reuze S, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. *Ann Oncol* 2017;28:1191–1206.
- [22] Peng J, Zhang J, Zhang Q, Xu Y, Zhou J, Liu L. A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma. *Diagn Intervent Radiol* 2018;24:121–127.

- [23] Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018;68:723–750.
- [24] Fehr D, Veeraraghavan H, Wibmer A, Gondo T, Matsumoto K, Vargas HA, et al. Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. *PNAS* 2015;112: E6265–6273.
- [25] Lin X, Yang F, Zhou L, Yin P, Kong H, Xing W, et al. A support vector machine-recursive feature elimination feature selection method based on artificial contrast variables and mutual information. *J Chromatogr B: Anal Technol Biomed Life Sci* 2012;910:149–155.
- [26] Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Medical Decis Making* 2006;26:565–574.
- [27] Zhou Y, He L, Huang Y, Chen S, Wu P, Ye W, et al. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. *Abdominal Radiol* 2017;42:1695–1704.
- [28] Akai H, Yasaka K, Kunimatsu A, Nojima M, Kokudo T, Kokudo N, et al. Predicting prognosis of resected hepatocellular carcinoma by radiomics analysis with random survival forest. *Diagn Interventional Imaging* 2018;99:643–651.
- [29] Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2017.
- [30] Zhao H, Hua Y, Dai T, He J, Tang M, Fu X, et al. Development and validation of a novel predictive scoring model for microvascular invasion in patients with hepatocellular carcinoma. *Eur J Radiol* 2017;88:32–40.
- [31] Du M, Chen L, Zhao J, Tian F, Zeng H, Tan Y, et al. Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. *BMC Cancer* 2014;14:38.